Preliminary data suggest that these tissue products play a significant role by suppressing the inflammatory response while also directly inhibiting the excitation of nerve cells that cause pain.
Miami, FL – August 17, 2020 – Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue-based products, announced today that Yun Guan, MD, PhD, professor of anesthesiology and critical care medicine, and professor of neurological surgery at the Johns Hopkins University School of Medicine, has been awarded a 5-year R01 grant from the National Institutes of Health (NIH) for a study titled “Birth Tissue Products for Non-opioid Treatment of Post-surgical Pain.” Dr. Guan and his team will study the efficacy and molecular mechanism, thereby human birth tissue promotes wound healing and suppresses pain after surgical procedures. TissueTech will serve as a sub-contractor on the project.
Earlier studies conducted by Dr. Guan in collaboration with TissueTech suggest that TissueTech human birth tissue allografts promote wound healing while reducing pain sensitization. “The long-term goal of this research is to demonstrate the efficacy, receptor mechanisms, and safety of human birth tissue as well as the major matrix component, i.e., HC-HA/PTX3 in the birth tissue, in promoting wound healing and inhibiting post-surgical pain,” said Dr. Guan. “I am especially proud to collaborate with Dr. Scheffer Tseng and his team at TissueTech on this initiative. In the context of our nation’s current opioid epidemic, healthcare providers face challenges of simultaneously optimizing postoperative pain management and limiting opioid use after surgery. Modifiable risk factors and novel non-opioid treatment options can reduce the risk of chronic opioid use after surgery. This is one reason that this study is so important.”
“Our collaborative efforts using various pre-clinical models also disclose that HC-HA/PTX3, a key bioactive compomnet in the birth tissue, is responsible for promoting regenerative healing by curtailing surgically-induced inflammation and nociceptive pain at the same time in this pre-clinical study,” said Dr. Tseng, the Chief Technology Officer of TissueTech.
The Research Project Grant (R01) is the original and historically oldest grant mechanism used by the NIH. It provides support for health-related research and development based on the mission of the NIH, which is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthens life, and reduce illness and disability.
About Amniox Medical, Inc.
Amniox Medical, Inc., a TissueTech, Inc. company, is a leader in the clinical application of human birth tissue-based products (amniotic membrane & umbilical cord) processed using TissueTech’s proprietary CRYOTEK® cryopreservation technology. Established in 2011, Amniox serves an unmet need for better surgical and therapeutic outcomes for chronic and complex wounds, orthopedics, sports medicine, spine, urology, gynecology, plastics, and general surgery. Connect with Amniox on our Website, Facebook, LinkedIn and Twitter.
About TissueTech, Inc.
TissueTech, Inc., the parent company of Amniox Medical, Inc. and Bio-Tissue, Inc., is a scientific and market leader in the field of regenerative medicine. TissueTech manufactures a broad range of ocular, surgical, wound care, and soft tissue products that are marketed under these subsidiaries. Since the company’s inception, clinicians have performed more than 500,000 human implants of the company’s products and published more than 360 peer-reviewed studies supporting its platform technology. TissueTech is committed to an unwavering culture of integrity that places our patients’ safety and clinical outcomes above all else. Learn more at https://tissuetech.com/.